Omeros Corporation Common Stock (OMER)

FairStock Score: 37/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I am wary of biotech stories that depend on one or two clinical bets, and Omeros fits that mold. It is a 175-employee company developing treatments for immunologic diseases; its lead candidate, Narsoplimab, targets TA-TMA, a transplant complication. A real moat would come from approved products, patents, and pricing power. Here, the moat is unproven. The recent numbers show a sharp turn: in fiscal Q1 2026, the quarter ended 2026-03-31, Omeros reported net income of $56.1M and diluted EPS of $0.62; in fiscal Q2 2026, the quarter ended 2026-06-30, it reported revenue of $28.5M, net income of $13.2M, and diluted EPS of $0.15. That is encouraging. But the latest full year, FY2025, ended 2025-12-31, still showed a net loss of $3.4M, following losses of $156.8M in FY2024 and $117.8M in FY2023. FairStock labels it a TURNAROUND because the latest year was a loss after earlier profits. Financial health is not comforting: trailing free cash flow is -$68.7M, FCF yield -5.0%, FairStock ROCE -18.68%, Altman Z -1.22, and Piotroski 5/9. At the $18.88 close on 2026-10-13, FairStock's P/E is 15.48 and PEG 0.10, with a FairStock Score of 37/100. The price is not demanding if those recent profits persist, but profits without cash flow and a beta of 2.57 deserve a margin of safety. I would need evidence that Narsoplimab can become a durable commercial product, and that cash burn reverses, before calling this a high-quality business.

In plain English: Omeros is a small drug company working on immune-related treatments, including one for a serious transplant complication. It lost money in its latest full year but has reported profits in the past two quarters, so the business looks unsteady but recently improved. At $18.88, the stock price is about 15 times recent earnings, which looks moderate, though cash is still going out the door and the shares are risky.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer